Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.045 USD | -2.34% | -7.59% | -25.00% |
05-09 | Transcript : Bluebird bio, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-06 | Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.00% | 206M | |
+7.20% | 113B | |
+10.97% | 106B | |
+0.82% | 22.27B | |
-12.18% | 22.22B | |
-5.61% | 19.43B | |
-37.85% | 17.87B | |
-5.59% | 17.24B | |
+6.95% | 14.29B | |
+35.07% | 12.52B |
- Stock Market
- Equities
- BLUE Stock
- News bluebird bio, Inc.
- Wells Fargo Adjusts Bluebird Bio Price Target to $5 From $8, Maintains Equal Weight Rating